By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluidigm this week said that it has formed a wholly owned subsidiary in China and has begun direct service to customers in that country. The subsidiary is called Fluidigm (Shanghai) Instrument Technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.